Home / Healthcare / Axillary Hyperhidrosis - Pipeline Review, H1 2015

Axillary Hyperhidrosis - Pipeline Review, H1 2015

Published: Apr 2015 | No Of Pages: 47 | Published By: Global Markets Direct

Axillary Hyperhidrosis - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Axillary Hyperhidrosis - Pipeline Review, H1 2015', provides an overview of the Axillary Hyperhidrosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Axillary Hyperhidrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Axillary Hyperhidrosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Axillary Hyperhidrosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Axillary Hyperhidrosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Axillary Hyperhidrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Axillary Hyperhidrosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Axillary Hyperhidrosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Axillary Hyperhidrosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Axillary Hyperhidrosis Overview 6
Therapeutics Development 7
Pipeline Products for Axillary Hyperhidrosis - Overview 7
Pipeline Products for Axillary Hyperhidrosis - Comparative Analysis 8
Axillary Hyperhidrosis - Therapeutics under Development by Companies 9
Axillary Hyperhidrosis - Pipeline Products Glance 10
Clinical Stage Products 10
Axillary Hyperhidrosis - Products under Development by Companies 11
Axillary Hyperhidrosis - Companies Involved in Therapeutics Development 12
Actavis plc 12
Brickell Biotech, Inc. 13
Dermira Inc. 14
GlaxoSmithKline plc 15
Revance Therapeutics, Inc. 16
TheraVida, Inc. 17
Axillary Hyperhidrosis - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
ANT-1403 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
BBI-4000 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
DRM-04 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
onabotulinumtoxin A - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
oxybutynin chloride - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
RT-001 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
solifenacin - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
umeclidinium bromide - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Axillary Hyperhidrosis - Recent Pipeline Updates 37
Axillary Hyperhidrosis - Dormant Projects 41
Axillary Hyperhidrosis - Product Development Milestones 42
Featured News & Press Releases 42
Feb 05, 2015: Dermira Announces Positive Phase 2b Results for DRM04 in Patients with Hyperhidrosis 42
Jan 12, 2015: Revance Therapeutics Provides Clinical Program Milestone Update For RT001 43
Sep 24, 2014: Brickell Biotech Announces Positive Preliminary Results of a Pilot Clinical Study of BBI-4000 for the Treatment of Hyperhidrosis 44
Mar 19, 2014: Anterios Announces Development Of Next Generation Injectable Botulinum Product 44
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 46
Disclaimer 47

Number of Products under Development for Axillary Hyperhidrosis, H1 2015 7
Number of Products under Development for Axillary Hyperhidrosis - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Clinical Stage Development, H1 2015 10
Products under Development by Companies, H1 2015 11
Axillary Hyperhidrosis - Pipeline by Actavis plc, H1 2015 12
Axillary Hyperhidrosis - Pipeline by Brickell Biotech, Inc., H1 2015 13
Axillary Hyperhidrosis - Pipeline by Dermira Inc., H1 2015 14
Axillary Hyperhidrosis - Pipeline by GlaxoSmithKline plc, H1 2015 15
Axillary Hyperhidrosis - Pipeline by Revance Therapeutics, Inc., H1 2015 16
Axillary Hyperhidrosis - Pipeline by TheraVida, Inc., H1 2015 17
Assessment by Monotherapy Products, H1 2015 18
Number of Products by Stage and Target, H1 2015 20
Number of Products by Stage and Mechanism of Action, H1 2015 22
Number of Products by Stage and Route of Administration, H1 2015 24
Number of Products by Stage and Molecule Type, H1 2015 26
Axillary Hyperhidrosis Therapeutics - Recent Pipeline Updates, H1 2015 37
Axillary Hyperhidrosis - Dormant Projects, H1 2015 41

Number of Products under Development for Axillary Hyperhidrosis, H1 2015 7
Number of Products under Development for Axillary Hyperhidrosis - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Clinical Stage Development, H1 2015 10
Assessment by Monotherapy Products, H1 2015 18
Number of Products by Top 10 Targets, H1 2015 19
Number of Products by Stage and Top 10 Targets, H1 2015 20
Number of Products by Top 10 Mechanism of Actions, H1 2015 21
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 22
Number of Products by Top 10 Routes of Administration, H1 2015 23
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 24
Number of Products by Top 10 Molecule Types, H1 2015 25
Number of Products by Stage and Top 10 Molecule Types, H1 2015 26

Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +